Dollar Tree (NASDAQ:DLTR) was upgraded by Goldman Sachs (NYSE:GS) to buy from neutral with a price target of $48 as the firm believes that the stock has been oversold.
Shares are higher by about 1.8 percent.
Myriad Genetics (NASDAQ:MYGN) was upgraded by Bank of America/Merrill Lynch to buy from neutral with a price target of $32 as the company should be able to expand and diversify while adding to earnings.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.